Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa

• Egile Nagusiak: Lijuan Yu (Egilea), Xuehua Yang (Egilea), Lu Xia (Egilea), Jie Zhong (Egilea), Wensong Ge (Egilea), Jianxin Wu (Egilea), Hongchun Liu (Egilea), Fei Liu (Egilea), Zhanju Liu (Egilea)
• Formatua: Liburua
• Argitaratua: Hindawi Limited, 2015-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn's disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn's disease activi...